Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-13
2009-06-30
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07553847
ABSTRACT:
The present invention provides methods for treating social anxiety disorder, comprising administering 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-5-hydroxy-2-oxohexyl) -1-isoindolinone or pharmaceutically acceptable salt, or optical isomer therof, and optionally comprising administering another compound for the treatment of social anxiety disorder that is a GABA agonist.
REFERENCES:
patent: 5494915 (1996-02-01), Barreau et al.
patent: 4960915 (1996-03-01), Bourzat et al.
patent: 5498716 (1996-03-01), Comte et al.
patent: 2003/0092719 (2003-05-01), Day et al.
patent: 2305859 (1997-04-01), None
patent: WO 93/01187 (1993-01-01), None
patent: WO 93/01189 (1993-01-01), None
patent: WO 93/01198 (1993-01-01), None
patent: WO 93/05041 (1993-03-01), None
patent: WO 93/11125 (1993-06-01), None
patent: WO 94/05663 (1994-03-01), None
patent: 99/63933 (1999-12-01), None
patent: WO 01/08670 (2001-02-01), None
Van Ameringen et al., Expert Opinion on Investigative Drugs, 9(10) (2000), pp. 2215-2231.
Pagoclone citation (entered in Registry file May 10, 1991).
Doctor's Guide to the Internet, located at http://www.docguide.com (Nov. 20, 1997).
Dunner, D.L., Depression and Anxiety, (Mar. 2001), 13(2), pp. 57-71.
Clary Cathryn M.
Donevan Sean
Eisman Perry S.
Kavoussi Richard
Ma Lyou-Fu
Foley & Lardner LLP
Indevus Pharmaceuticals, Inc.
Reid Steven M.
Spivack Phyllis G.
Villacorta Gilberto M.
LandOfFree
Use of pagoclone for the treatment of social anxiety disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of pagoclone for the treatment of social anxiety disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pagoclone for the treatment of social anxiety disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4121903